IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
White, Harvey D.1,2; Held, Claes3,4; Stewart, Ralph1,2; Tarka, Elizabeth5; Brown, Rebekkah1; Davies, Richard Y.5; Budaj, Andrzej8; Harrington, Robert A.9; Steg, P. Gabriel10,11,14; Ardis-Sino, Diego15; Armstrong, Paul W.16; Avezum, Alvaro19; Aylward, Philip E.21; Bryce, Alfonso22; Chen, Hong23; Chen, Ming-Fong24; Corbalan, Ramon25; Dalby, Anthony J.26; Danchin, Nicolas12,13; De Winter, Robbert J.27; Denchev, Stefan28; Diaz, Rafael30; Elisaf, Moses31; Flather, Marcus D.32,33; Goudev, Assen R.29; Granger, Christopher B.7; Grinfeld, Liliana34; Hochman, Judith S.35; Husted, Steen36; Kim, Hyo-Soo37; Koenig, Wolfgang38; Linhart, Ales39,40; Lonn, Eva1; Lopez-Sendon, Jose41; Manolis, Athanasios J.42; Mohler, Emile R., III43; Nicolau, Jose C.20; Pais, Prem44; Parkhomenko, Alexander45; Pedersen, Terje R.46,47; Pella, Daniel48; Ramos-Corrales, Marco A.49; Ruda, Mikhail50; Sereg, Mtys51; Siddique, Saulat52; Sinnaeve, Peter53; Smith, Peter1; Sritara, Piyamitr54; Swart, Henk P.55; Sy, Rody G.56; Teramoto, Tamio57; Tse, Hung-Fat58; Watson, David1; Weaver, W. Douglas59; Weiss, Robert60; Viigimaa, Margus61; Vinereanu, Dragos62; Zhu, Junren63; Cannon, Christopher P.64,65; Wallentin, Lars3,4; STABILITY Investigators1
刊名NEW ENGLAND JOURNAL OF MEDICINE
2014-05-01
DOI10.1056/NEJMoa1315878
370期:18页:1702-1711
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者GlaxoSmithKline ; GlaxoSmithKline
研究领域[WOS]General & Internal Medicine
关键词[WOS]ACTIVATING-FACTOR ACETYLHYDROLASE ; PHOSPHOLIPASE A(2) ; ATHEROSCLEROTIC PLAQUE ; CLINICAL-OUTCOMES ; OXIDIZED LDL ; LIPOPROTEIN ; RISK ; INHIBITOR ; THERAPY ; TRIAL
英文摘要

BackgroundElevated lipoprotein-associated phospholipase A(2) activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A(2).

MethodsIn a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization).

ResultsDuring a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02).

ConclusionsIn patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.)

语种英语
资助者GlaxoSmithKline ; GlaxoSmithKline
WOS记录号WOS:000335405200008
引用统计
被引频次:165[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52367
专题北京大学第二临床医学院_心血管内科
作者单位1.Queen Giovanna Univ Hosp, Dept Cardiol, Sofia, Bulgaria
2.Oslo Univ Hosp, Ctr Prevent Med, Oslo, Norway
3.ECLA Estudios Cardiol Latinoamer, Rosario, Santa Fe, Argentina
4.Norwich Med Sch, Norwich, Norfolk, England
5.Norwich Univ Hosp, Norwich, Norfolk, England
6.Univ Buenos Aires, Sch Med, Buenos Aires, DF, Argentina
7.Safarik Univ, Fac Med, Dept Med 1, Kosice, Slovakia
8.NYU Langone Med Ctr, Dept Med, New York, NY USA
9.San Jose Satelite Hosp, Naucalpan, Mexico
10.Hosp Unit West, Dept Med, Herning Holstbro, Denmark
11.Charles Univ Prague, Fac Med 1, Prague, Czech Republic
12.Hosp Univ La Paz, IdiPaz, Dept Cardiol, Madrid, Spain
13.Asklepe Hosp, Dept Cardiol, Athens, Greece
14.Russian Cardiol Res & Prod Complex Rosmedtechnol, Moscow, Russia
15.St George Hosp, LIFE Hlth Ctr, Szekesfehervar, Hungary
16.Shaikh Zayed Postgrad Med Inst, Lahore, Pakistan
17.McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
18.Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
19.Antonius Hosp, Dept Cardiores, Sneek, Netherlands
20.Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil
21.Cardiol Clin El Golf, Lima, Peru
22.Milpark Hosp, Johannesburg, South Africa
23.Univ Hosp Alexandrovska, Clin Cardiol, Sofia, Bulgaria
24.St Johns Med Collage, Bangalore, Karnataka, India
25.Inst Cardiol, Kiev, Ukraine
26.Univ Oslo, Oslo, Norway
27.Teikyo Acad Res Ctr, Itabashi Ku, Tokyo, Japan
28.Maine Res Associates, Auburn, AL USA
29.Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China
30.Harvard Univ, Sch Med, Boston, MA USA
31.Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1142, New Zealand
32.Univ Auckland, Auckland 1, New Zealand
33.Uppsala Univ, Dept Med Sci, Uppsala, Sweden
34.Uppsala Clin Res Ctr, Uppsala, Sweden
35.GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, King Of Prussia, PA USA
36.GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, Res Triangle Pk, NC USA
37.Duke Univ, Med Ctr, Durham, NC USA
38.Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland
39.Stanford Univ, Dept Med, Stanford, CA 94305 USA
40.Hop Bichat Claude Bernard, AP HP, Dept Hospitalouniv FIRE, INSERM Unite 1148, F-75877 Paris, France
41.Univ Paris Diderot, Sorbonne Paris Cite, Paris, France
42.Hop Europeen Georges Pompidou, AP HP, INSERM Unite 970, Paris, France
43.Univ Paris 05, Paris, France
44.Azienda Osped Univ Parma, Parma, Italy
45.Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada
46.McMaster Univ, Dept Med, Hamilton, ON, Canada
47.Royal Brompton Hosp, ICMS, NHLI Imperial Coll, London SW3 6LY, England
48.Univ Sao Paulo, Sch Med, Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil
49.Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
50.Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100871, Peoples R China
51.Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
52.Pontificia Univ Catolica Chile, Div Cardiovasc, Santiago, Chile
53.Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
54.Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece
55.Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
56.Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89069 Ulm, Germany
57.Charles Univ Prague, Gen Univ Hosp, Dept Med 2, Dept Cardiovasc Med, Prague, Czech Republic
58.Katholieke Univ Leuven Hosp, Dept Cardiovasc Med, Leuven, Belgium
59.Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med, Bangkok 10400, Thailand
60.Univ Philippines, Coll Med, Dept Med, Manila, Philippines
61.Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Cardiol, Hong Kong, Hong Kong, Peoples R China
62.Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA
63.Tallinn Univ Technol, North Estonia Med Ctr, EE-19086 Tallinn, Estonia
64.Univ Med & Pharm, Univ & Emergency Hosp, Bucharest, Romania
65.Brigham & Womens Hosp, Thrombolysis Myocardial Infarct Study Grp, Boston, MA 02115 USA
推荐引用方式
GB/T 7714
White, Harvey D.,Held, Claes,Stewart, Ralph,et al. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease[J]. NEW ENGLAND JOURNAL OF MEDICINE,2014,370(18):1702-1711.
APA White, Harvey D..,Held, Claes.,Stewart, Ralph.,Tarka, Elizabeth.,Brown, Rebekkah.,...&STABILITY Investigators.(2014).Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease.NEW ENGLAND JOURNAL OF MEDICINE,370(18),1702-1711.
MLA White, Harvey D.,et al."Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease".NEW ENGLAND JOURNAL OF MEDICINE 370.18(2014):1702-1711.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[White, Harvey D.]的文章
[Held, Claes]的文章
[Stewart, Ralph]的文章
百度学术
百度学术中相似的文章
[White, Harvey D.]的文章
[Held, Claes]的文章
[Stewart, Ralph]的文章
必应学术
必应学术中相似的文章
[White, Harvey D.]的文章
[Held, Claes]的文章
[Stewart, Ralph]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。